Broad Institute Comprehensive Screening Center

21世纪的生物医学研究人员工作在人类疾病认识爆炸的震中。与人类和各种感染性生物一样，相关基因组的完整序列为下一步探索疾病的分子机制奠定了基础。布罗德研究所的研究人员在这场革命的早期阶段认识到，对小分子表型变化背后的细胞通路的扰动将使剖析细胞电路和疾病生物学成为可能，从而使纠正人类疾病的道路向前迈进。在过去的十年里，我们在开放的数据共享环境中以生产模式运营了一个筛选设施，创建了第一个全面和公开的小分子数据库和分析环境，其中包含2000多万个结合和分析井测量、一个新的化学生物学信息模型和许多强大的分析工具，并在2007年在人员、筛选自动化、LIMS和机器人方面进行了大量投资，大大提高了这些已经很重要的生产能力。这个筛查设施位于一个专注于小分子和小分子筛查的丰富环境中，与疾病生物学和基因组生物学相结合。我们在这里提出了一项计划，在哈佛大学和麻省理工学院的博德研究所(BCSC)运营一个全面筛查中心，通过与更广泛的MLPCN研究社区合作，利用和补充现有的组织和基础设施倡议。

Biomedical researchers in the 21st century work in the epicenter of an explosion in the understanding of human disease. The complete sequences of relevant genomes, like the human and various infectious organisms, lay the foundation for the next steps in probing molecular mechanisms of disease. Broad Institute researchers recognized at an early stage of this revolution that the perturbation of the cellular pathways that underlie phenotypic changes with small molecules will make it possible to dissect cell circuitry and disease biology, thus enabling a path forward to correcting human diseases. We have operated a Screening Facility in a production mode over the past ten years in an open data-sharing environment, created the first comprehensive and public small-molecule database and analysis environment containing over 20 million binding and assay-well measurements, a novel chemical biology information model and many powerful analysis tools, and, in 2007, made a substantial investment in personnel, screening automation, LIMS and robotics that has substantially increased these already significant production capabilities. This screening facility resides within a rich environment focused on small molecules and small-molecule screening integrated with disease biology and genome biology. We propose here a plan to operate a Comprehensive Screening Center at the Broad Institute of Harvard and MIT (BCSC), leveraging and complementing existing organizational and infrastructure initiatives by collaborating with a wider MLPCN research community.